Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Long COVID and Dyslipidemia: Risks and Burdens

admin by admin
April 3, 2023
in News


The following is a summary of the “Risks and burdens of incident dyslipidaemia in long COVID: a cohort study,” published in the January 2023 issue of Diabetes and Endocrinology by Xu, et al.


Post-acute COVID-19 (i.e., >30 days after SARS-CoV-2 infection) has been linked to an increased risk of dyslipidemia, according to animal and human studies with short follow-ups. However, no large-scale controlled studies are currently available that assess the risks and burdens of incident dyslipidemia in the post-acute phase of COVID-19. As a result, we set out to investigate the incidence of post-acute COVID-19-related dyslipidemia in SARS-CoV-2 survivors and the associated risks and burdens over a 12-month period. Patients who tested positive for COVID-19 and survived the first 30 days after infection were included in the study’s cohort (n=51 919) along with a non-infected contemporary control group (n=2,647,654) enrolled between March 1, 2020, and January 15, 2021, and a historical control group (n=2,539,941) enrolled between March 1, 2018, and January 15, 2019. 

All 3 cohorts’ participants were dyslipidaemic-free at enrollment, and there was no evidence of SARS-CoV-2 infection in the control groups. As a next step, they estimated the risks and 1-year burdens of incident dyslipidemia, lipid-lowering medication use, and a composite of these outcomes using inverse probability weighting with predefined and algorithmically-selected high dimensional variables. They reported hazard ratios (HRs) and 12-month burdens per 1,000 people as risk measures. Based on the treatment environment for the acute infection, we also estimated the risks and burdens of incident dyslipidemia outcomes in distinct subgroups (i.e., participants who were non-hospitalized, hospitalized, or admitted to intensive care during the acute phase of SARS-CoV-2 infection).

Total cholesterol > 200 mg/dL (hazard ratio [HR] 1.26, 95% CI 1.22-1.29; burden 22.46, 95% CI 19.14-25.87 per 1000 people at 1 year in COVID-19 vs. non-infected contemporary controls; p<.0001), triglycerides > 150 mg/dL (HR 1.27, 95% CI 1.23-1.31; p< .0001).

A combination of these abnormal lipid laboratory results carried a 1 in 24 (95% CI 1 in 21- 1 in 27) risk and a 39 in 19 (95% CI 34 in 71-43 in 73) burden. The risk and burden of incident use of lipid-lowering medications both increased (hazard ratio [HR] 1.54; 95% confidence interval [CI] 1.48-1.61; burden 2.550; 95% CI 2.261-28.50). The burden of dyslipidemia was estimated to be 54.03% (95% CI 49.21%-58.892%) and the hazard ratio was 1.31% (95% CI 1.28%-1.34) for any dyslipidemia outcome (laboratory abnormality or lipid-lowering medication use). The acute phase of COVID-19 infection was correlated with the risks and burdens of these long-term outcomes (i.e., whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Analyses comparing the COVID-19 group to the non-infected historical control group yielded consistent results. Their results suggest that in the COVID-19 infection’s post-acute phase, there are increased risks and 1-year burdens of incident dyslipidemia and the use of lipid-lowering medications. Dyslipidaemia is a possible post-acute sequela of SARS-CoV-2 infection and should be addressed in the post-acute care of patients with COVID-19.

Source: sciencedirect.com/science/article/pii/S2213858722003552



Source link

Advertisement Banner
Previous Post

CMS finalizes Medicare Advantage 2024 rate notice

Next Post

Amwell CEO Roy Schoenberg on CVS Health, M&A opportunities

Related Posts

News

Factors Associated with Recurrences or Relapses in Individuals Diagnosed with GCA

June 1, 2023
News

Examining Independently Billed Dermatologic Procedures by Nonphysician Practitioners in the US

May 31, 2023
News

Long-Term Use of Antiseizure Medication and the Risk of Developing Type 2 Diabetes Mellitus

May 30, 2023
News

TC Response in IBD Children Treated with Infliximab and Adalimumab After Treatment Adjustment

May 29, 2023
News

Spironolactone may be effective in the treatment of acne vulgaris

May 28, 2023
News

Quizartinib improves overall median survival in patients with acute myeloid leukemia

May 27, 2023
Next Post

Amwell CEO Roy Schoenberg on CVS Health, M&A opportunities

Recommended

Neuroinflammation Worsens Pain in Chemotherapy Patients

2 months ago

SPM-Creative Learning Exchange, Portland, OR (& virtual), July 16 – The Health Care Blog

1 week ago

Recent layoffs raise questions on industry’s job outlook

2 months ago

Nurse Anesthetist Salary and Career Outlook

6 months ago

4 Reasons Dentists Need to Use a Medical Suction Pump During Oral Surgery

5 months ago

© Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.